Narendra Modi has emphasized that India’s pharmaceutical sector is undergoing a major transformation, moving from being known as the “pharmacy of the world” to emerging as a global hub for innovation.
Highlighting the sector’s evolution, the Prime Minister noted that India is no longer limited to supplying affordable generic medicines at scale but is steadily advancing toward research-driven growth and high-value innovation.
He underlined the increasing focus on research and development (R&D), biologics, biosimilars, and next-generation therapies, which are expected to drive the next phase of growth in the pharmaceutical industry.
The remarks came as PM Modi shared an article by Union Health Minister Jagat Prakash Nadda, describing it as a reflection of how India is preparing to lead the global pharmaceutical race.
The article highlights that sustained policy support and government initiatives have helped reshape the sector’s trajectory, encouraging investment in advanced research capabilities and complex drug development.
India’s pharmaceutical industry, long recognized for its strength in generic medicines, is now moving up the value chain by focusing on innovation-led growth. This includes expanding into biologics and biosimilars—segments expected to play a crucial role in the future of global healthcare.
With increasing emphasis on innovation, technology, and research, India is positioning itself not just as a manufacturing powerhouse but as a key player in shaping the future of the global pharmaceutical ecosystem.
